Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Pain 14Multiple Myeloma 12Pain, Postoperative 10Neoplasms 9Agnosia 8Lymphoma, Non-Hodgkin 6Lung Neoplasms 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Cancer Pain 5Breast Neoplasms 5Neoplasm Metastasis 4Lymphoma 4Leukemia 4Hodgkin Disease 4Head and Neck Neoplasms 4Burkitt Lymphoma 4Prostatic Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Lymphoma, B-Cell 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Hairy Cell 3Hematologic Neoplasms 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Trigger Finger Disorder 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Philadelphia Chromosome 2Myelodysplastic Syndromes 2Melanoma 2Lymphoma, Mantle-Cell 2

Interventions

Rituximab 416Cyclophosphamide 348Vincristine 173Prednisone 172Doxorubicin 168Etoposide 160Peripheral Blood Stem Cell Transplantation 114Filgrastim 108Lenalidomide 97fludarabine phosphate 96Radiotherapy 80Cytarabine 80Gemcitabine 73Melphalan 66Mycophenolic Acid 64Cyclosporine 60Methotrexate 59Busulfan 57Ifosfamide 55Carmustine 55fludarabine 50Tacrolimus 50Whole-Body Irradiation 49Carboplatin 49polatuzumab vedotin 44Oxaliplatin 44Dexamethasone 44Antilymphocyte Serum 42ibrutinib 40Bendamustine Hydrochloride 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, Large B-Cell, Diffuse × Acetaminophen × Clear all
NCT04660799 2023-10-12

A Study on Pharmacokinetics (PK), Efficacy and Safety of Subcutaneous (SC) Versus Intravenous (IV) Rituximab, in Combination With CHOP (Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) in Previously Untreated Participants With CD20 Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Hoffmann-La Roche

Phase 2 Completed
50 enrolled 25 charts
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT00482053 2018-05-14

Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT

Stanford University

Phase 2 Terminated
3 enrolled 13 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡